TCR Therapy

Multivalent gamma-delta T-cells: promising agents for the treatment of cancers 0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells 1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
Optimizing the upscaling and outscaling of CAR T-cell therapies 4:06
Optimizing the upscaling and outscaling of CAR T-cell therapies
Saskia Rösch • 6 Apr 2022
Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma 2:30
Moving CAR T-cell therapies to earlier lines of therapy in multiple myeloma
Angela Krackhard • 6 Apr 2022
Developing individualized cancer therapies with neoantigen-specific TCRs 4:27
Developing individualized cancer therapies with neoantigen-specific TCRs
Angela Krackhard • 6 Apr 2022
Improving immune-imaging tools to assess cancer immunotherapies 5:33
Improving immune-imaging tools to assess cancer immunotherapies
Angela Krackhard • 6 Apr 2022
Overcoming barriers in treating liquid tumors with T-cell therapies 2:20
Overcoming barriers in treating liquid tumors with T-cell therapies
Michela Consonni • 1 Apr 2022
The anti-leukemic potential of CD1c-restricted T cells 3:05
The anti-leukemic potential of CD1c-restricted T cells
Michela Consonni • 1 Apr 2022
Harnessing lipid-specific TCRs to target CD1c-expressing leukemia 5:36
Harnessing lipid-specific TCRs to target CD1c-expressing leukemia
Michela Consonni • 1 Apr 2022
Targeting WT1 peptides for TCR-based AML therapy 2:04
Targeting WT1 peptides for TCR-based AML therapy
Chiara Bonini • 1 Apr 2022
TCR redirected T cells for cancer therapy 1:46
TCR redirected T cells for cancer therapy
Chiara Bonini • 1 Apr 2022
Adoptive T cell therapies for solid tumors: what are the key challenges? 1:38
Adoptive T cell therapies for solid tumors: what are the key challenges?
Chris Klebanoff • 1 Apr 2022
The use of CRISPR-Cas9 technology in the development of T cell therapies 0:55
The use of CRISPR-Cas9 technology in the development of T cell therapies
Alessio Nahmad • 31 Mar 2022
Accelerating the identification of clinically relevant T cell therapies 2:17
Accelerating the identification of clinically relevant T cell therapies
Elvira D’Ippolito • 31 Mar 2022
Genome editing to address challenges with adoptive T-cell therapy 3:02
Genome editing to address challenges with adoptive T-cell therapy
Chiara Bonini • 22 Nov 2021
TCR gene editing in cancer therapy 3:04
TCR gene editing in cancer therapy
Chiara Bonini • 22 Nov 2021
The content of VJRegenMed is intended for healthcare professionals